Biodexa Pharmaceuticals PLC (BDRX)
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business